Literature DB >> 2237118

Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review.

D A Haake1, P C Zakowski, D L Haake, Y J Bryson.   

Abstract

The effect of early acyclovir therapy on the course of varicella pneumonia in previously healthy adults was assessed. Medical records from five university-affiliated medical centers were retrospectively reviewed; included were all immunocompetent adults with a clinical diagnosis of primary varicella, a chest radiograph consistent with varicella pneumonia, and an arterial blood gas measurement indicating significant hypoxia. Of the 38 patients who met the study criteria, 11 had had a course of intravenous acyclovir initiated within the first 36 hours of hospitalization; the mean time from admission to initiation of therapy in this early-treatment group was 9.6 hours. The group that received early acyclovir treatment had a lower mean temperature beginning on the fifth day of hospitalization (37.0 degrees C vs. 37.7 degrees C; P = .011) and a lower mean respiratory rate beginning on the sixth day of hospitalization (21 vs. 28 respirations per minute; P = .004). Early acyclovir therapy also resulted in a significant improvement in oxygenation beginning on the sixth day of hospitalization in patients with follow-up arterial blood gas measurements (P = .035). Thus, early institution of acyclovir therapy is associated with reduction in fever and tachypnea and improvement in oxygenation in otherwise healthy adults with varicella pneumonia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237118     DOI: 10.1093/clinids/12.5.788

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  39 in total

1.  Life-threatening chickenpox pneumonitis in two previously healthy adults.

Authors:  J Hunter; S A Stott
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 2.  Chickenpox pneumonia: case report and literature review.

Authors:  P A Nee; P J Edrich
Journal:  J Accid Emerg Med       Date:  1999-03

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  Cutting Edge: Fetal/Placental Type I IFN Can Affect Maternal Survival and Fetal Viral Load during Viral Infection.

Authors:  Karen Racicot; Paulomi Aldo; Ayman El-Guindy; Ja-Young Kwon; Roberto Romero; Gil Mor
Journal:  J Immunol       Date:  2017-03-06       Impact factor: 5.422

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children.

Authors:  A Y Tan; C J Connett; G J Connett; S C Quek; H K Yap; F Meurice; B W Lee
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

7.  Towards universal childhood immunization against chickenpox?

Authors:  B J Law
Journal:  Paediatr Child Health       Date:  2000-07       Impact factor: 2.253

Review 8.  Risks associated with viral infections during pregnancy.

Authors:  Karen Racicot; Gil Mor
Journal:  J Clin Invest       Date:  2017-05-01       Impact factor: 14.808

9.  Varicella pneumonitis in an immunocompetent patient.

Authors:  I Masih; R Boyle; A Donnelly; A Soye; J Kidney
Journal:  BMJ Case Rep       Date:  2011-03-03

10.  Pregnancy-specific transcriptional changes upon endotoxin exposure in mice.

Authors:  Kenichiro Motomura; Roberto Romero; Adi L Tarca; Jose Galaz; Gaurav Bhatti; Bogdan Done; Marcia Arenas-Hernandez; Dustyn Levenson; Rebecca Slutsky; Chaur-Dong Hsu; Nardhy Gomez-Lopez
Journal:  J Perinat Med       Date:  2020-09-25       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.